archive-com.com » COM » A » AGENDIA.COM

Total: 235

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Agendia’s MammaPrint & BluePrint Tests for Breast Cancer Highlighted at Personalized Medicine Conference | Agendia
    Management outlined how BluePrint and MammaPrint greatly improve the physician s ability to personalize treatment to the specific biology of each breast cancer Molecular subtyping provides us more information about each individual patient s breast cancer than is available from traditional biomarkers Dr Barth said By combining the information from BluePrint and MammaPrint we can better predict the benefits of therapy This means we can personalize treatment and in some cases confidently assure patients they can avoid chemotherapy and the side effects that go with it because other therapies will be more effective MammaPrint provides definitive High Risk or Low Risk information about breast cancer recurrence without ambiguous intermediate results The BluePrint test building on the foundational prognostic precision of MammaPrint classifies breast cancer into one of four molecular subtypes Luminal A Luminal B HER2 type and Basal type BluePrint also provides information about neoadjuvant chemosensitivity that is responsiveness to chemotherapy more accurately than does an IHC FISH assessment Among the research studies cited by Dr Barth was one presented at the recent San Antonio Breast Cancer Symposium by Massimo Cristofanilli M D Director of the Breast Care Center at Thomas Jefferson University Hospitals Ann Meredith an executive at a Philadelphia area nonprofit and a patient of Dr Cristofanilli s was one of the patients who has benefited from the new diagnostics Her initial oncologist recommended her breast cancer be treated with chemotherapy and radiation and she gave serious consideration to having a double prophylactic mastectomy After consulting with Dr Cristofanilli and receiving the MammaPrint and BluePrint tests however she learned she had a Luminal A molecular subtype of breast cancer That meant she had a low risk of recurrence and did not need to undergo chemotherapy or a mastectomy Meredith said receiving a personalized diagnosis gave her peace of mind that she and Dr Cristofanilli made the right treatment decisions and that she can move on with her life without unnecessary concern about her cancer recurring My treatment was not cookie cutter she said The MammaPrint and BluePrint tests changed the recommendations on whether to do chemotherapy and whether I should have mastectomy or a breast conserving lumpectomy Symphony Agendia s suite of genomic tests that includes MammaPrint and BluePrint is the only predictive multi gene breast cancer panel that is validated in prospective trials including outcome data The Agendia tests have substantial insurance coverage encompassing an estimated 170 million lives and including coverage by Medicare and regional and national insurers The PMWC conference was held Jan 27 28 in Mountain View Calif About Agendia Agendia is a leading molecular diagnostic company that develops and markets FFPE based genomic diagnostic products which help support physicians with their complex treatment decisions Agendia s breast cancer Symphony suite was developed using unbiased gene selection analyzing the complete human genome ensuring 100 definitive results for cancer patients Symphony includes MammaPrint the first FDA cleared IVDMIA breast cancer recurrence assay as well as BluePrint a molecular subtyping assay and TargetPrint an ER PR

    Original URL path: http://www.agendia.com/agendias-mammaprint-blueprint-tests-for-breast-cancer-highlighted-at-personalized-medicine-conference-2/ (2016-05-01)
    Open archived version from archive


  • News and Press Releases | Agendia - Part 7
    Announces Presentation of Data Highlighting Symphony Suite of Genomic tests MammaPrint BluePrint and TargetPrint at San Antonio Breast Cancer Symposium 12 09 2013 Ten Scientific Posters Document Study Results on Second Generation Symphony Suite Containing Multi Gene Signatures to Provide Molecular Subtyping IRVINE CA and AMSTERDAM THE NETHERLANDS December 9 2013 New breast cancer research incorporating the SymphonyTM suite of genomic tests MammaPrint BluePrint Continued Multiple International Breast Cancer Guidelines Confirm Use of Agendia Tests for Prognostic Predictive Information in Cancer Treatment Decisions 09 19 2013 Important Role of Molecular Subtyping in Determining the Need for Chemotherapy also Cited IRVINE CA and AMSTERDAM THE NETHERLANDS September 9 2013 Agendia a leader in molecular cancer diagnostics today announced that multiple established international breast cancer treatment guidelines Continued Researchers Identify Splice Variant of Breast Cancer Gene that Can Mask Risk of Recurrence 08 27 2013 High Risk Patients with Unusual Hormone Receptors May Be Undertreated IRVINE CA and AMSTERDAM THE NETHERLANDS August 27 2013 Agendia a leader in molecular cancer diagnostics announced today that researchers have identified a subset of breast cancer patients whose Continued Molecular Subtyping Can Help Determine Prognosis and Chemotherapy Benefit in Colorectal Cancer Patients 06 05 2013 CHICAGO

    Original URL path: http://www.agendia.com/agendia-news-and-press-releases/page/7/ (2016-05-01)
    Open archived version from archive

  • News and Press Releases | Agendia - Part 8
    today announced that results from five studies focused on breast colon and colorectal cancer will be presented at the upcoming American Society of Clinical Oncology ASCO Continued Agendia Reports More Than 20 000 MammaPrint Breast Cancer Recurrence Results 05 02 2013 IRVINE CA May 2 2013 Agendia a world leader in molecular cancer diagnostics today announced that it has reported more than 20 000 MammaPrint breast cancer results including approximately 6 000 in 2012 alone The MammaPrint test analyzes 70 key genes Continued Study shows half of early stage breast cancer patients may be able to avoid chemotherapy 02 25 2013 Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction MammaPrint breast cancer test ID s women who can avoid chemotherapy 02 12 2013 KARE Minneapolis St Paul 2013 This TV report tells how you can know your breast cancer better through this genomic personalized medicine test which is part of the Symphony suite of breast cancer tests Study Shows Half of Early Stage Breast Cancer Patients May Safely Avoid Chemotherapy 02 04 2013 IRVINE CA and AMSTERDAM THE NETHERLANDS February 4 2013 The MammaPrint breast cancer test can dramatically reduce the number of women who need to

    Original URL path: http://www.agendia.com/agendia-news-and-press-releases/page/8/ (2016-05-01)
    Open archived version from archive

  • Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers | Agendia
    of breast tumors as a predictor for tumor response to targeted chemotherapies MammaPrint MINT study assesses the ability of molecular profiling and traditional pathologic and clinical prognostic factors to predict patient response to neo adjuvant chemotherapy Genomic profiling of breast cancer in African American women It is clear that molecular subtypes are key pieces of information in determining the best course of treatment for breast cancer patients and that subtyping will only become more important as hundreds of targeted therapies reach the market in the coming decade said Agendia CEO David Macdonald The posters discussions covering colorectal and colon cancer include Intrinsic subtypes of colorectal cancer that direct different treatment strategies The use of ColoPrint as a predictor of outcome and chemotherapy benefit in stage II and III colon cancer patients Like breast cancer where molecular classification into subtypes has clear relevance for prognosis and treatment we are finding clinically relevant subtypes for colorectal and colon cancer Macdonald added Agendia has a rich history of presenting innovative and ground breaking research that benefits oncologists and their cancer patients A more complete list of presentation abstracts can be found on ASCO s website at www asco org About Agendia Agendia is a leading molecular diagnostic company that develops and markets FFPE based genomic diagnostic products Agendia s breast cancer Symphony suite was developed by analyzing the complete human genome ensuring 100 definitive results for cancer patients Together these tests help physicians determine a patient s individual risk for metastasis which patients will benefit from chemo hormonal or combination therapy and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods In addition to the Symphony suite of tests Agendia has a rich pipeline of genomic products in development The Company collaborates

    Original URL path: http://www.agendia.com/ground-breaking-research-identifies-molecular-subtyping-as-a-key-to-determining-prognosis-and-benefit-of-chemotherapy-for-breast-and-colorectal-cancers-2/ (2016-05-01)
    Open archived version from archive

  • Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results | Agendia
    has definitely provided a spark in the marketplace Macdonald said The RASTER study shows that MammaPrint accurately identifies half of breast cancer patients who can safely forgo chemotherapy with excellent outcome That data has given physicians and oncologists throughout the world confidence in the ability of MammaPrint to determine risk and to guide therapeutic choices The success of MammaPrint has also driven growth in the other genomic diagnostic products that make up Agendia s Symphony suite of tests including BluePrint and TargetPrint More than 85 percent of Agendia customers using MammaPrint also order BluePrint and TargetPrint to obtain vital genomic information used in treatment decisions added Macdonald About MammaPrint MammaPrint is the first and only FDA cleared IVDMIA breast cancer recurrence assay The unique 70 gene signature of MammaPrint provides clinicians with a second generation tool that stratifies a much broader range of early stage breast cancer patients into either a low risk vs high risk of distant cancer recurrence following surgery This test goes well beyond the first generation 21 gene test by accurately providing guidance for patients who have the more challenging estrogen receptor low or negative and Her 2 positive patients Furthermore MammaPrint evaluates all of the critical molecular pathways involved in the formation of potentially lethal metastasis as opposed the more limited first generation tests It is equally accurate in formalin fixed parrafin embedded tissues as it was originally in fresh and frozen tissue This provides equal access for breast surgeons as well as medical oncologists to offer this critical analysis to patients About Agendia Agendia is a leading molecular diagnostic company that develops and markets FFPE based genomic diagnostic products Agendia s breast cancer Symphony suite was developed using unbiased gene selection analyzing the complete human genome ensuring 100 definitive results for cancer patients Together

    Original URL path: http://www.agendia.com/agendia-reports-more-than-20000-mammaprint-breast-cancer-recurrence-results/ (2016-05-01)
    Open archived version from archive

  • News and Press Releases | Agendia - Part 9
    2013 IRVINE CA and AMSTERDAM THE NETHERLANDS January 25 2013 Agendia a world leader in molecular cancer diagnostics today announced the addition of Dr Neil M Barth as its Chief Medical Officer In this role Dr Barth will translate complex Continued Study Indicates Breast Cancer Diagnosis Is More Accurate with New Genomic Tests 12 07 2012 SAN ANTONIO The latest generation of genomic tests for breast cancer can improve physicians ability to diagnose the disease and more precisely tailor each patient s treatment according to a study being presented at the 2012 CTRC AACR San Antonio Breast Cancer Symposium Continued Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium 09 13 2012 AMSTERDAM THE NETHERLANDS and IRVINE CA September 13 2012 Agendia an innovative molecular cancer diagnostics company and leader in personalized medicine announced today that they will present five posters on genomic research studies in breast cancer at the American Society of Continued Agendia Brings Together Thought Leaders in Molecular Diagnostics and Medical Oncology 08 29 2012 IRVINE CA and AMSTERDAM THE NETHERLANDS August 29 2012 Agendia an innovative molecular cancer diagnostics company and leader in personalized medicine

    Original URL path: http://www.agendia.com/agendia-news-and-press-releases/page/9/ (2016-05-01)
    Open archived version from archive

  • Agendia Appoints Dr. Neil M. Barth MD, FACP, as Chief Medical Officer | Agendia
    a medical staff of 1 400 physicians and 4 400 nurses With a strong background in the basic sciences health informatics clinical and regulatory standards combined with the requisite business acumen Dr Barth has been at the forefront transforming the practice and business of medicine in several key areas Dr Barth is board certified in Internal Medicine Hematology and Medical Oncology In addition to his medical background he is a prolific author and co author and a noted speaker facilitator moderator and presenter for a vast array of healthcare management and clinical forums As we enter our next phase of expansion we are thrilled to add Dr Barth to our executive team said David Macdonald Agendia s Chief Executive Officer Dr Barth s wealth of experience will guide our efforts as we continue to develop Agendia s rich product pipeline to answer key clinical questions for physicians About Agendia Agendia is a leading molecular diagnostic company that develops and markets FFPE based genomic diagnostic products which help support physicians with their complex treatment decisions Agendia s breast cancer Symphony suite was developed using unbiased gene selection analyzing the complete human genome ensuring 100 definitive results for cancer patients Symphony includes MammaPrint the first and only FDA cleared IVDMIA breast cancer recurrence assay as well as BluePrint a molecular subtyping assay TargetPrint an ER PR HER2 expression assay and TheraPrint an alternative therapy selection assay Together these tests help physicians determine a patient s individual risk for metastasis which patients will benefit from chemo hormonal or combination therapy and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods In addition to the Symphony suite of tests Agendia has a rich pipeline of genomic products in development The Company collaborates with

    Original URL path: http://www.agendia.com/agendia-appoints-dr-neil-m-barth-md-facp-as-chief-medical-officer/ (2016-05-01)
    Open archived version from archive

  • News and Press Releases | Agendia - Part 10
    ISO 13485 certification for all activities Continued Agendia Appoints Dr Stefan Glück to Chair Medical Advisory Board 08 09 2012 IRVINE CA and AMSTERDAM THE NETHERLANDS August 9 2012 Agendia an innovative molecular cancer diagnostics company and leader in personalized medicine today announced that Stefan Glück MD PhD will lead the company s Medical Advisory Board As Chairman Dr Glück Continued Agendia Welcomes Dr Mark Gittleman to Expanding Medical Advisory Board 07 10 2012 IRVINE CA and AMSTERDAM THE NETHERLANDS July 10 2012 Agendia an innovative molecular cancer diagnostics company and leader in personalized medicine today announced that Dr Mark Gittleman Medical Director of Breast Care Specialists and Advanced Breast Care Imaging has Continued Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance 07 09 2012 IRVINE CA and AMSTERDAM THE NETHERLANDS July 9 2012 Agendia an innovative molecular cancer diagnostics company and leader in personalized medicine today announced a key addition to their executive team with the appointment of Glen Fredenberg as CFO and Continued Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction 06 01 2012 Agendia s Microarray based Gene Expression Profile Provides Critical Additional Information for Treatment Decisions for Stage II

    Original URL path: http://www.agendia.com/agendia-news-and-press-releases/page/10/ (2016-05-01)
    Open archived version from archive



  •